Intellia Therapeutics (NTLA) Prices 4.1M Share Offering at $145/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
June 29, 2021 9:08 PM EDTCAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $145.00 per share. Intellia also granted the underwriters a 30-day option to purchase up to an additional 620,689 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are... More
